Trial Profile
A Phase 1b Randomized, Double-Blinded, Placebo Controlled, Multi-Cohort Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Jan 2022
Price :
$35
*
At a glance
- Drugs Lenacapavir (Primary) ; Bictegravir/emtricitabine/tenofovir alafenamide
- Indications HIV-1 infections
- Focus Proof of concept; Therapeutic Use
- Sponsors Gilead Sciences
- 13 Jan 2022 Results published in the Journal of Antimicrobial Chemotherapy
- 08 Oct 2020 Results of resistance analysis presented at the 15th International Congress on Drug Therapy and HIV Infection
- 30 Sep 2020 According to a Gilead Sciences media release, data from this study will pe presented at the HIV Glasgow 2020 conference.